Evonile Pharma

₹1,819As of Sun 8 Nov 2026, 12:00 UTC

NSE:EVONILEHealthcare

Country India

PE (Fwd) 44.33

TSR 6Y CAGR 22.52%

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) —

PE TTM 48.20

TSR TTM —

Mkt cap ₹45.96B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹2,012

10.60%

(86.95%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

41.86

34.50

40.87

37.74

2878.50%

(17.58%)

18.44%

(7.65%)

Revenue₹B

3.787

3.351

3.563

3.543

(5.28%)

(11.53%)

6.33%

(0.54%)

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

3.543

Revenue₹B

—

3.999

3.787

3.351

3.563

3.543

3.591

(2.98%)

(0.54)

Revenue growth%

—

(5.28)

(11.53)

6.33

(0.54)

1.36

(2.91)

—

44.02

Gross margin%

—

55.44

46.75

40.32

43.07

44.02

43.74

44.02

26.64

Operating margin%

—

5.94

15.86

18.78

25.13

26.64

26.95

18.78

26.30

Net margin%

—

(0.93)

27.29

25.42

28.32

26.30

27.18

26.30

48.20

P/E ratio (avg)x

—

16.09

21.22

—

46.01

18.66

—

47.57

EV/EBITx

—

85.39

27.69

28.73

—

46.40

28.73

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

37.74

EPS₹

—

(1.51)

41.86

34.50

40.87

37.74

39.53

(3.40%)

—

(7.65)

EPS growth%

—

2878.49

(17.58)

18.44

(7.65)

4.75

5.39

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

10.00

25.00

—

35.72%

—

Div yield (avg)%

—

1.22

1.48

3.41

—

1.48

—

Payout ratio%

—

23.89

72.46

61.18

—

42.53

—

24.69

Shares (diluted)M

—

24.69

◌24.69

—

Buyback yield%

—

◌—

—

D/E ratiox

—

44.91

Enterprise value₹B

—

20.30

16.63

18.08

—

44.91

(5.63%)

—

LT debt₹M

—

Peers (US$463.4M)

Cap (US$)

Gufic Biosciences…

459.3M

58.86x

RPG Life Sciences…

450.8M

38.23x

Aarti Drugs Limited

433.3M

17.80x

Zhuhai Rundu Pharmaceu…

466.4M

234.0x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

74.93

42.23

Own earn%

—

Sh yield%

—

0.74

Owners

Insiders/Inst%

—

0.68

Short interest%

—

SBC / revenue%

0.07

Record

10Y

Profitable years

4/5

Revenue growth years

1/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

6–27

$1 testx

—

Incr. ROIC%

—

Evonile Pharma Limited is involved in the pharmaceutical business in India and internationally. It operates Pharma International (Commercial operations), Development (Drug development), Biomedical Research, and Operations. The company offers therapeutic products in the areas of bone and pain under the Voveran brand; transplantation immunology under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹3.543B

(2.98%)

1.00×

Cost of revenue

₹1.984B

2.72%

1.26×

Operating expenses

₹615.5M

(25.32%)

0.35×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m